WebAmount: $485,720.00. DESCRIPTION (provided by applicant): Emergence of antibiotic-resistance has created a medical crisis. Life-threatening bacterial pathogens, such as … WebStockholders can obtain these documents when they are filed and become available free of charge from the SEC’s website at www.sec.gov, or from Cubist upon written request to …
CBST Cubist Pharmaceuticals Inc. - Stocktwits
WebMar 23, 2024 · CUBIST PHARMACEUTICALS INC (NASDAQ:) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share CUBIST PHARMACEUTICALS INC Nasdaq: Nasdaq WebOct 24, 2011 · Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in ... in wall mailbox
Cubist Pharmaceuticals LinkedIn
WebModerna. Moderna, Inc. ( / məˈdɜːrnə / mə-DUR-nə) [4] là một công ty công ty công nghệ sinh học của Mỹ có trụ sở tại Cambridge, Massachusetts, tập trung vào phương pháp điều trị RNA, chủ yếu là vắc-xin mRNA. Những vắc-xin này sử dụng một bản sao của phân tử gọi là RNA thông tin ... Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA. . The company employed 638 people, mostly in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion). See more Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors. Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to … See more The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with See more WebCubist Pharmaceuticals Inc. said last week that it had reached an agreement with Pfizer Inc. to develop and sell antibacterial drugs. The terms were not disclosed. in wall magazine rack bathroom